Current reimbursement models in general do not accommodate many of the unique factors common among gene and cell therapies. In this second article of a three-part series, CRA’s Lev Gerlovin discusses the challenges to demonstrating value and addressing affordability and discuss options for payment models.
The authors wish to acknowledge the contributions of Stephanie Donahue, Michael Krepps, Walter Colasante, and Pascale Diesel to this article.
Click here to read the article.
